within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF01_Tretinoin;

model Tretinoin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 1.5e-05,
    adminDuration = 600,
    adminMass = 45 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005333333333333333,
    Tlag = 1320,
    Vdp = 0.0025,
    k12 = 2.9999999999999997e-06,
    k21 = 2.9999999999999997e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tretinoin</td></tr><tr><td>ATC code:</td><td>L01XF01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>45</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>900</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tretinoin (all-trans retinoic acid) is a derivative of vitamin A used primarily in the treatment of acute promyelocytic leukemia (APL) as a differentiation agent under the ATC code L01XF01. Its use in oncology is distinct from topical use for acne or dermatology. It is approved for intravenous and oral administration in acute promyelocytic leukemia.</p><h4>Pharmacokinetics</h4><p>Reported for adult patients with acute promyelocytic leukemia receiving oral tretinoin therapy.</p><h4>References</h4><ol><li><p>Napolitano, M, et al., &amp; Patruno, C (2022). Alitretinoin for the treatment of severe chronic eczema of the hands. <i>Expert opinion on pharmacotherapy</i> 23(2) 159–167. DOI:<a href=\"https://doi.org/10.1080/14656566.2021.1998457\">10.1080/14656566.2021.1998457</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34789049/\">https://pubmed.ncbi.nlm.nih.gov/34789049</a></p></li><li><p>Regazzi, MB, et al., &amp; Liberati, AM (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. <i>Clinical drug investigation</i> 16(1) 25–33. DOI:<a href=\"https://doi.org/10.2165/00044011-199816010-00004\">10.2165/00044011-199816010-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18370515/\">https://pubmed.ncbi.nlm.nih.gov/18370515</a></p></li><li><p>Rigas, JR, et al., &amp; Warrell, RP (1993). Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. <i>Journal of the National Cancer Institute</i> 85(23) 1921–1926. DOI:<a href=\"https://doi.org/10.1093/jnci/85.23.1921\">10.1093/jnci/85.23.1921</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8230282/\">https://pubmed.ncbi.nlm.nih.gov/8230282</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XF01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tretinoin;
